强骨胶囊干预老年低骨量患者的临床疗效

Clinical Efficacy of Qianggu Capsule in Treatment of Elderly Patients with Low Bone Mass

目的:观察强骨胶囊干预老年低骨量患者的临床疗效。方法:79例老年低骨量患者随机分为2组:治疗组40例,对照组39例。治疗组使用强骨胶囊(1粒/次,3次/d),同时予以基础治疗—钙尔奇D(1粒/d)及阿法迪三软胶囊(1粒/d);对照组予以基础治疗—钙尔奇D(1粒/d)及阿法迪三软胶囊(1粒/d);疗程均为6个月。结果:1)治疗组在中医症候积分改善方面明显优于对照组(P<0.05)。2)经过治疗治疗组骨密度下降不明显,对照组骨密度下降,两组比较差异有统计学意义(P<0.05)。3)治疗组能增加患者6min步行距离,明显优于对照组(P<0.05)。4)两组在骨折发生率、骨代谢生化标志物以及不良反应方面无明显差异。结论:强骨胶囊干预治疗可减缓骨量丢失,改善临床症状,提高患者运动能力。

Objective：To observe the clinical efficacy of Qianggucapsule in the treatment of elderly patients with low bone mass. Methods= 79 elderly patients with low bone mass were randomly divided into the treatmem group （40 cases）and the control group（39 cases）. The treatment group used Qianggu capsule （Is,rid）as well as the basic treatment of CahrateD （1 grain / day） and α-D3 soft capsules （1 grain/ day）;The control group underwent Cahrate D （1 grain / day） andα-D3 soft capsules （1 grain/ day）. Both with a course of six months. Results： 1）The improvemenl of Chinese symptom scores in the treatment group is obvious better than that in the control group（P 〈0.05）. 2）The bone mineral density in treatment group had no significant decline while the control group decreased, and the difference was statistically significant （P〈 0.05）. 3）The si〉minute walk distance in the treatment group increased and it was significantly better than that in the control group （P〈0.05）. 4）There was no significant difference in fracture incidence, biochemical markers of bone metab olism and adverse reactions. Conclusion： Qianggu capsule intervention can reduce bone loss, improve clinical symptoms and increase exercise capacity of patients.